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February 21, 2006:884–92aken together, our findings show that BNP and NT-proBNP
oncentrations increase with decreasing weight. This is likely to be
ue to decreased cardiac production of BNP, suggesting some yet
ndefined beneficial effects of obesity in HF that clearly warrant
urther study.
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The Underestimated Impact of Smoking and Smoking Cessation on the Risk of Secondary
Cardiovascular Disease Events in Patients With Stable Coronary Heart Disease:hort Studyo the Editor: Numerous studies have reported beneficial effects
f smoking cessation in terms of decreased cardiovascular morbid-
ty and mortality in patients with coronary heart disease (1).
owever, all of these studies primarily relied on self-reported
moking status. Additionally, changes in smoking status during
ollow-up were often not considered in the analysis. Both limita-
ions bear the potential for misclassification of smoking behavior
nd thus for dilution of differences between continuous smokers
nd quitters and for underestimation of the beneficial effect of
moking cessation. The aim of our analysis was to assess the impact
f smoking and smoking cessation on the risk of secondary cardio-
ascular disease (CVD) events by combining self-reported smoking
ata with measurements of a biomarker for active smoking (serum
otinine), and by accounting for changes in smoking status during the
ollow-up period.
We conducted a prospective cohort study among 1,206 patients
58% of eligible) age 30 to 70 years participating in a 3-week
n-patient rehabilitation (rehab) in two rehab clinics in Germany
everal weeks after acute manifestation of coronary heart disease
CHD) (2). Baseline data were collected at rehab admission and
ischarge, and active follow-up was conducted one and three years
fter rehab discharge. Four methods were used to categorize. Self-reported smoking status at the beginning of rehab only:
never smokers, former smokers (ex-smokers who had quit
before the acute manifestation of CHD), recent quitters
(ex-smokers who quit after the acute manifestation of CHD),
or continued smokers (smokers who did not quit until the
beginning of rehab).
. Serum cotinine levels at rehab discharge: 15 ng/ml 
smoker; 15 ng/ml  nonsmoker (3).
. Baseline smoking status based on both self-report and serum
cotinine measurements: Analogous to (A), but patients were
reclassified as continued smokers if they were cotinine positive
at rehab discharge, and self-reported continued smokers were
reclassified as recent quitters, if they were cotinine negative at
the end of rehab.
. Analogous to (C), but patients who changed smoking status
during follow-up (according to serum cotinine at one-year
follow-up) were excluded.
Secondary CVD events during follow-up were defined as death
rom CVD (International Classification of Diseases, 9th revision,
ositions 390 to 459) or a nonfatal myocardial infarction or
schemic cerebrovascular event (stroke or transient ischemic at-
ack), both as reported by the primary care physician.
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February 21, 2006:884–92To study associations between smoking status and the occur-
ence of secondary CVD events during the first three years after
ehab discharge, we employed the Cox proportional hazards model
sing the SAS procedure PHREG (SAS Institute, Cary, North
arolina). Associations were derived in bivariate and multivariable
odels, with adjustment for those variables that were shown to be
mportant in a forward selection procedure (two-sided p value of
he log-likelihood statistic 0.2).
A total of 1,029 patients with complete data on self-reported
moking and cotinine levels and follow-up data on CVD events
85% of the 1,206 recruited participants) were included in analysis.
edian follow-up time was 1,137 days. Mean age was 59 years,
able 1. Self-Reported Smoking Status at the Beginning of
ehabilitation and Smoking Status According to Cotinine Level
t the End of Rehabilitation
Self-Reported
Smoking Status at
Rehab Admission n (%)
Serum Cotinine Level at
Rehab Discharge*
n Positive
(Row %)
n Negative
(Row %)
ontinued smokers 48 (4.7) 27 (56.3) 21 (43.8)
ecent quitters† 197 (19.1) 52 (26.4) 145 (73.6)
ormer smokers‡ 454 (44.1) 44 (9.7) 410 (90.3)
ever smokers 330 (32.1) 19 (5.8) 311 (94.2)
otal 1,029 142 (13.8) 887 (86.2)
Serum cotinine 15 ng/ml  negative; serum cotinine 15 ng/ml  positive.
Persons who quit smoking after the clinical manifestation of coronary heart disease
t baseline. ‡Persons who quit smoking before the clinical manifestation of coronary
eart disease at baseline.
able 2. Association Between Smoking and Fatal or Nonfatal Se
efinition of Smoking Status
n
CVD
Events
. Self-reported smoking status at baseline
Continued smokers 48 4
Recent quitters† 197 14
Former smokers‡ 454 37
Never smokers 330 13
. Smoking status according to cotinine level at baseline
Smokers 142 13
Nonsmokers 887 55
. Reclassified smoking status according to cotinine measurements at bas
Continued smokers 142 13
Recent quitters† 166§ 7
Former smokers‡ 410 35
Never smokers 311 13
. Analogous to (C), but excluding patients who changed smoking status
Continued smokers 98 12
Recent quitters† 107 6
Former smokers‡ 361 33
Never smokers 286 12
Adjusted for age, gender, history of diabetes, triglyceride level, total cholesterol lev
nhibitors. Owing to missing values in these variables, 56 observations were excluded
HD at baseline. ‡Persons who quit smoking before the clinical manifestation of CH
oth cotinine negative.
CHD  coronary heart disease; CI  confidence interval; CVD  cardiovascular disea5% were male, and 58% had suffered a myocardial infarction.
ccording to self-report at rehab admission, about one-third of
atients had never smoked regularly (Table 1). Among self-
eported current smokers, 44% were cotinine negative at rehab
ischarge, suggesting smoking cessation during rehab, and 26%,
0%, and 6% of self-reported recent quitters, former smokers, and
ever smokers, respectively, were cotinine positive, indicating
elapse during rehab or misreporting of smoking status. After
eclassification of all cotinine-positive patients to continued smok-
rs and cotinine-negative self-reported smokers to recent quitters,
0% of participants were categorized as never smokers, 40% as
ormer smokers, about 15% as recent quitters, and 15% as
ontinued smokers.
Among the participants categorized as continued smokers at
ehab, 37% stopped smoking during the first year after rehab, and
9% of recent quitters, 13% of former smokers, and 9% of never
mokers were found to be cotinine positive at one-year follow-up.
During the three-year follow-up period, 68 patients were
ffected by secondary CVD events, of which 17 were fatal.
ndependent of the definition, smoking status was associated with
he occurrence of a secondary CVD event, but the strength of
ssociation increased with increasing strictness of definition (Table 2).
n the final adjusted analysis, the hazard ratios were 0.42 for recent
uitters, 0.51 for former smokers, and 0.26 for never smokers
ompared to continued smokers (p value for trend 0.005).
Our results are in line with findings reported in a recently
ublished meta-analysis (1) and corroborate and strongly extend
arlier findings from the same cohort regarding the short-term
ffects of smoking (2). In this previous analysis, which had been
ary CVD Events in Patients with CHD According to
Crude Hazard Ratio
(95% CI)
Adjusted Hazard Ratio*
(95% CI)
1.00 1.00
0.82 (0.27–2.50) 0.87 (0.28–2.67)
0.92 (0.33–2.59) 0.66 (0.23–1.92)
0.44 (0.14–1.33) 0.37 (0.12–1.14)
p value for trend: 0.02
1.00 1.00
0.64 (0.35–1.16) 0.50 (0.26–0.96)
1.00 1.00
0.44 (0.17–1.09) 0.45 (0.17–1.17)
0.88 (0.47–1.67) 0.63 (0.31–1.27)
0.42 (0.20–0.91) 0.36 (0.16–0.81)
p value for trend: 0.03
g the first year of follow-up
1.00 1.00
0.42 (0.16–1.12) 0.42 (0.15–1.15)
0.67 (0.34–1.29) 0.51 (0.25–1.08)
0.30 (0.13–0.66) 0.26 (0.11–0.62)
p value for trend: 0.005
-density lipoprotein cholesterol level, and intake of angiotensin-converting enzyme
ultivariate regression. †Persons who quit smoking after the clinical manifestation of
baseline. §145 self-reported recent quitters plus 21 self-reported continued smokers,cond
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February 21, 2006:884–92estricted to secondary CVD events during the first year after
ischarge from rehab and which had included coronary artery
evascularization procedures besides myocardial infarction, stroke,
nd CVD death as end points, we also had observed a decreased
isk in patients who never smoked (odds ratio [OR]  0.44), who
eported former smoking (OR  0.64), and who were categorized
s recent quitters (OR  0.71) in comparison with continued
mokers. The current study, which is based on a much longer
ollow-up, an exclusive focus on “hard” disease endpoints, and the
se of repeated measurements of smoking status, suggests that
ertinent risk reductions may be even stronger in the long run.
The proportions of cotinine-positive subjects in the group of
elf-reported never smokers at rehab (6%) and at one-year
ollow-up (9%) may serve as estimates for the proportion of
eceivers (persons misreporting their smoking status). Although
alse-positive test results cannot be ruled out, exposure to environ-
ental tobacco smoke, which may have a major impact on
rognosis, is unlikely to cause a serum cotinine level as high as our
utpoint (4). The finding that 20% of patients changed smoking
tatus in the first year of follow-up further underlines the
elatively high dynamics of smoking status shortly after the
ccurrence of CHD.
We conclude that the impact of smoking abstinence on long-
erm prognosis of patients with CHD may be considerably larger
han suggested by previous studies which relied on self-reports of
moking status. Our results underline the importance of efforts to
upport smoking cessation and to prevent relapse in patients with
oronary heart disease.
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nti-Inflammatory Action of
ngiotensin-Converting Enzyme Inhibitors
nd Angiotensin Receptor Blockers
he meta-analysis by Healey et al. (1) indicated that both
ngiotensin-converting enzyme inhibitors (ACEIs) and angioten-
in receptor blockers (ARBs) appear to be effective in the preven-
ion of atrial fibrillation. However, among the plausible underlying
echanisms, they did not mention the potential role of low-grade
ystemic inflammation.
Increasing levels of C-reactive protein (CRP), the classic marker
f systemic inflammation, have been shown to be associated with
trial fibrillation (2,3). Furthermore, CRP appears also to predict
atients at increased risk for developing future atrial fibrillation (4).
Because angiotensin receptor blockade has been shown to be
elated to a decrease in markers of systemic inflammation (5,6),
his anti-inflammatory action may help explain the beneficial effect
f ACEIs and ARBs in the prevention of atrial fibrillation.
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revention of Atrial Fibrillation by
ngiotensin-Converting Enzyme Inhibitors
nd Angiotensin II Receptor Blockers
e read with great interest the report by Healey et al. (1) in which
hey presented a meta-analysis of published randomized trials involv-
ng the prevention of atrial fibrillation (AF) with angiotensin-
